Six groups of speakers participate in US Food and Drug Administration (FDA) advisory meetings: (1) FDA staff, (2) employees of the sponsoring company, (3) voting members, (4) patient and consumer representatives, (5) public speakers, and (6) experts speaking on behalf of a pharmaceutical company. Financial conflict of interest has been established in all but one of these groups, specifically voting members, 1 patient and consumer representatives, 2 and public speakers. 3 Among FDA staff, subsequent employment in the biopharmaceutical industry is prevalent. 4 And, all employees of the sponsoring company are, by definition, conflicted. To our knowledge, no investigation has focused on experts speaking on behalf of a pharmaceutical company, in terms of either the extent of their financial conflict of interest or whether it is correlated with metrics of academic reputation and success.
Methods. We reviewed transcripts, presentation slides, and supplemental documents for all Oncology Drug Advisory Committee (ODAC) meetings concerning a specific drug product held between January 1, 2011, and December 31, 2015. We identified each presented drug, pharmaceutical company, meeting date, and presenter, and whether each presenter was an FDA employee, a pharmaceutical company employee, or an expert speaking on behalf of a pharmaceutical company. Searches were conducted for the first 4 nonemployee speakers invited by each sponsor in both ProPublica's Dollars for Docs (includes payments from August 2013 through December 2014) and the Scopus databases. We recorded each speaker's payments received, number of published articles, h-index, and total citations. Finally, we used Google to identify the year each speaker graduated from medical school (a marker of seniority). Statistical analyses were performed using Stata statistical software, version 13.0 (StataCorp).
Results. We reviewed 35 ODAC meetings held between 2011 and 2015, identifying 182 unique speakers who spoke on behalf of 31 companies regarding 46 unique drugs. Of those speakers, 53 (29.1%) were FDA employees, 83 (45.6%) were pharmaceutical company employees, and 46 (25.3%) were experts speaking on behalf of a pharmaceutical company. Of the experts, 4 were international health care professionals, and 4 did not have MD degrees. We performed our analysis on the 38 experts who were based in the United States and had an MD degree. Of the 38 experts, 35 (92.1%) received industry payments, and 18 (47.4%) had documented payments from the specific sponsoring company. One observation (payment in excess of $2 million) was omitted because analysis using leverage and Cook distance revealed that this observation met outlier criteria.
Of 37 experts speaking on behalf of a pharmaceutical company, the mean income from the industry was $39,316 (median, $35,435), the median number of published articles was 275, the median h-index was 56, and the median career citation count was 12,020. Correlations between the number of published articles, total citations, h-index, and industry payments were examined in univariate analysis (Table) . These correlations remained significant in multivariate analyses in which the regression models were adjusted for the number of years since medical school graduation, a measure of seniority (Table; all P<.001). Figure 1 presents the univariate relationships graphically. Figure 2 presents a plot of the individual payments to these 37 physicians. 37  36  35  34  33  32  31  30  29  28  27  26  25  24  23  22  21  20  19  18  17  16  15  14  13  12  11  10  9  8  7  6  5  4  3  2  1 Speaker Industry payments FIGURE 2. The amount of payments made to 37 experts speaking on behalf of pharmaceutical companies. One person (not shown) met outlier criteria, with payments received of $2.8 million.
Discussion. We found that most (92.1%) expert speakers at FDA ODAC meetings receive sizable industry payments (median, $35,435). We were unable to establish payments made from the specific sponsoring company to 20 of the 38 experts (52.6%), which may be a result of the limited time frame in which payments were reported. In addition, the Physician Payments Sunshine Act's 5 disclosure requirement does not apply to drug companies that do not yet have a drug on the US market, a category that includes several sponsors we examined.
We found that among the elite experts at ODAC meetings, strong correlations exist between metrics of academic success (publications/citations/h-index) and industry payments. After adjusting for seniority, these correlations remained significant (P<.001). These results raise the question of whether the industry pursues highly influential physicians or whether the acceptance of financial conflict improves one's academic output, through publications derived from collaboration. Future work is needed to explore the direction of this relationship.
Bisphosphonates and Osteonecrosis of the Jaw
To the Editor In the January 2017 issue of Mayo Clinic Proceedings, Goodwin et al 1 provide reassuring information on the incidence of osteonecrosis of the jaw (ONJ) in patients treated with intravenous bisphosphonates. Although the causal relationship between this class of bone antiresorptive medications and ONJ has long been known, this specific complication of osteoporosis treatment appears to be a rarity. Nevertheless, the perception among patients and some health care professionals is that ONJ is a relatively common occurrence. Further, the often sensational description of ONJ leads many patients to refuse antiresorptive therapy simply because they fear development of ONJ, including some who have severe osteoporosis and are at high risk of fragility fractures.
Goodwin et al 1 identified evidence of osteonecrosis in only 0.42% of patients who had cancer and 0.05% of patients without cancer over 6 years of follow-up, ie, very low numbers in both groups. These data highlight ONJ's rarity, which should be strongly considered and reinforced when health care professionals have riskbenefit discussions about bisphosphonates with patients. These discussions should include the fact that the true incidence of ONJ remains very low, despite public perception, and that in a patient with osteoporosis, the risk of fracture is relatively high (a point mentioned by Goodwin et al 1 ) . Another important point to stress to patients is that a fracture does not involve merely the morbidity of a broken bone. Many patients and their loved ones do not realize that more than 20% of patients die in the first year after a hip fracture from complications surrounding the fracture and the resultant immobility, such as infection and thromboembolic events.
2-4 A significant number of patients also lose their long-term ability to live independently after a hip fracture. 5 The focus of osteoporosis treatment, therefore, is identification of patients at high risk for fracture and prevention of initial fracture and its subsequent potentially life-altering complications. All of these factors need to be considered by all parties when assessing a patient in whom bisphosphonate therapy may be indicated.
Although the risk of ONJ is real, one needs to compare that risk with the potential risk of a fracture and the problems that arise from it. The research by Goodwin et al 1 provides an additional layer of assurance that hopefully will encourage more receptive usage of antiresorptive drugs among those who have osteoporosis.
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